GlassScriptPhysician profile
Dang Hai DO
NPI 1821403544
$2,101.71
in general payments reported to CMS, 2019-2025
19 companies · $950 in 2025
The $950 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $238 · 2023: $359 · 2024: $425 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $615.58 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $434.45 | 2023-2025 | |
| Novo Nordisk INC | $130.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $124.93 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $105.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.42 | 2022-2024 | Jardiance |
| Amgen INC. | $98.08 | 2023-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $81.24 | 2023-2025 | |
| Gilead Sciences, INC. | $80.89 | 2022-2023 | |
| Lilly USA, LLC | $62.23 | 2025 | Mounjaro, Zepbound |
| Edwards Lifesciences Corporation | $58.14 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lundbeck LLC | $45.84 | 2024-2025 | Rexulti |
| Dexcom, INC. | $32.24 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $30.78 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $25.65 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.27 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $20.35 | 2025 | Cobenfy |
| Linus Health, INC. | $17.23 | 2024 | Core Cognitive Evaluation |
| Dynasplint Systems INC. | $17.18 | 2024 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dang DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.